Accurate Education - Nutraceutical Protocols: Multiple Sclerosis (MS)-associated pain

Nutraceutical Protocols:

Multiple Sclerosis (MS)-associated pain

Multiple Sclerosis (MS) causes significant, often chronic, pain for 29%-86% of patients, arising from damaged nerves (neuropathic) or muscle/joint strain (musculoskeletal). Common, often nighttime-worse symptoms include burning sensations, electric shocks (Lhermitte’s sign), spasms, and facial pain. Treatment involves medication, physiotherapy, and lifestyle adjustments.

See:

A Quick Review of Nutraceuticals

Nutraceutical Protocols:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

Nutraceutical protocols:

Multiple Sclerosis (MS)-Associated Pain

Multiple Sclerosis (MS) is associated with many different types of pain. The use of nutraceuticals offers limited Benedict for some of these pains as explored below.

Key Types of MS-Associated Pain

Neuropathic Pain (Nerve Damage): This is often described as burning, stabbing, tingling, or an electric-shock-like sensation.
1. Lhermitte’s Sign: A brief, intense, electric-shock-like sensation that runs down the spine when the neck is flexed.
2. Trigeminal Neuralgia: Intense, sharp facial pain often triggered by light touch.
3. Extremity Pain: Constant, burning, or aching sensations in the legs and arms.
Musculoskeletal Pain: Results from spasticity (muscle tightness) or, in some cases, from improper posture or compensation for weakness, causing pain in the back, joints, or muscles.
Paroxysmal Pain: Sudden, intense, short-lived pain episodes, such as muscle spasms or spasms of the limbs.
Headaches: Occur frequently, with migraines being three times more common in MS patients than in the general population.

Common Symptoms and Sensations

Burning/Tightening: Often described as a “tightening” band around the limbs or trunk.
Itching/Crawling: Abnormal sensations, sometimes described as insects crawling on the skin.
Spasms: Intense muscle cramps, particularly in the legs.

Pathophysiology Targeted:

Central demyelination, neuroinflammation, microglial activation, CaMKIIα-mediated pain signaling, IL-17-driven inflammation, oxidative stress, blood-brain barrier dysfunction, spinal cord and thalamic lesions, endoplasmic reticulum stress in dorsal root ganglia

Clinical Context:

Pain affects 50–86% of MS patients and significantly reduces quality of life.[1][2] MS-related pain is heterogeneous and includes:

(1) central neuropathic pain from CNS lesions (burning dysesthesias, ongoing extremity pain),

(2) paroxysmal pain (trigeminal neuralgia, Lhermitte’s phenomenon, painful tonic spasms),

(3) musculoskeletal pain from spasticity and abnormal gait, and

(4) treatment-related pain (injection site reactions).[1][2][3] Opioids show reduced efficacy in MS due to central amygdala microglial activation that attenuates morphine analgesia, particularly in females.[4]

This figure illustrates the cellular and molecular landscape within an MS lesion, showing the targets for both disease-modifying therapies and potential nutraceutical interventions

Figure 4 Cells, Molecules, and Therapies.

—

MECHANISTIC RATIONALE FOR NUTRACEUTICAL APPROACH

MS pain involves several mechanisms targetable by nutraceuticals:

1. CaMKIIα activation: Spinal CaMKIIα activity is enhanced in EAE, correlating with spontaneous and evoked pain. IL-17 acts upstream of CaMKIIα in pain generation. Curcumin directly inhibits CaMKIIα activity.[Document][6]

2. Microglial activation: Central amygdala microglial activation drives pain hypersensitivity and attenuates morphine analgesia in EAE. PEA, melatonin, and resveratrol suppress microglial activation.[4]

3. Neuroinflammation: Proinflammatory cytokines (TNF-α, IL-6, IL-17, IL-1β) drive MS pathology and pain. Multiple nutraceuticals target these pathways.[7]

4. Oxidative stress: Reactive oxygen species contribute to demyelination and pain. ALA, NAC, and resveratrol address oxidative stress.[8]

5. Blood-brain barrier dysfunction: BBB disruption allows immune cell infiltration. Resveratrol defends BBB integrity in EAE.[9]

6. Endoplasmic reticulum stress: ER stress in DRG contributes to pain hypersensitivity in EAE.[10]

—

NUTRACEUTICAL PROTOCOL FOR MS PAIN

Tier 1: Core Agents (Strongest Evidence in MS)

Agent	Dosing Protocol	Mechanism/Rationale	References
Palmitoylethanolamide (PEA)	600 mg BID) × 4 weeks → 600 mg QD (ultramicronized	MS Clinical evidence: Reduced IFN-β1a injection site pain; decreased IFN-γ, TNF-α, IL-17; Effective for nociceptive, neuropathic, and nociplastic pain	[1], [2], [3], [4]
Vitamin D3	High-dose: 100,000 IU every 2 weeks OR 50,000 IU weekly; 25(OH)D ≥ 40 ng/mL	D-Lay MS trial: Reduced disease activity (HR 0.66); Most benefit in severe deficiency (12 ng/mL); Modulates opioid signaling	[5], [6], [7], [8]
Alpha-Lipoic Acid (ALA)	1200 mg daily	MS clinical evidence: 68% reduction in brain atrophy in SPMS; reduced MMP-9, ICAM-1; anti-inflammatory; inhibits lymphocyte migration	[9], [10], [11], [12]
Melatonin	3–10 mg QHS	MS clinical evidence: Reduced oxidative stress, improved sleep, attenuated cardiac autonomic dysfunction; negatively correlates with MS relapses; blocks Th17 differentiation	[13], [14], [15], [16], [17]

[16][28][29][30][31] [32][33][34][35][36][37][38][39][40][7][41][8]

PEA Clinical Evidence in MS: A randomized, double-blind, placebo-controlled study in relapsing-remitting MS patients found that ultramicronized PEA added to IFN-β1a significantly improved pain sensation at injection sites, improved quality of life, and reduced circulating IFN-γ, TNF-α, and IL-17 levels. PEA also increased plasma levels of endogenous palmitoylethanolamide, anandamide, and oleoylethanolamide.[28]

Vitamin D Clinical Evidence: The D-Lay MS trial (2025) demonstrated that high-dose vitamin D (100,000 IU every 2 weeks) significantly reduced disease activity in clinically isolated syndrome (HR 0.66), with efficacy comparable to teriflunomide. Patients with severe vitamin D deficiency (<30 nmol/L) benefited most.[33]

Melatonin Clinical Evidence: A 12-week RCT showed melatonin (3 mg/night) significantly reduced oxidative stress markers (MDA, AOPP), improved glutathione levels, enhanced sleep quality and quantity, and attenuated cardiac autonomic dysfunction in MS patients.[40] Melatonin levels negatively correlate with MS relapse activity, and melatonin blocks pathogenic Th17 differentiation while boosting protective Tr1 cells.[39]

—

Tier 2: Anti-Inflammatory and Neuroprotective Agents

Agent	Dosing Protocol	Mechanism/Rationale	References
Curcumin	500 mg TID (high-bioavailability)	EAE evidence: Reduced Th17 cells, improved clinical course; Inhibits CaMKIIα (key pain mediator in MS); Inhibits NF-κB, AXL/JAK2/STAT3	[1], [2], [3], [4]
Omega-3 (EPA/DHA)	2 g daily	MS evidence: Higher serum ALA associated with lower CDMS risk (HR 0.60) and relapses; Reduced TNF-α; improved quality of life	[5], [6], [7], [8]
CoQ10	300–500 mg daily	MS clinical evidence: 500 mg/day reduced TNF-α, IL-6, MMP-9; Improved fatigue and depression in RRMS	[9]
Resveratrol	250–500 mg daily	EAE evidence: Defended BBB integrity; reduced clinical severity; suppressed iNOS, IL-1β; increased IL-10; downregulated NOX2/NOX4	[10], [11]

[6][7][42][43][44][45][46][47][48][9][49][50]

Curcumin Mechanistic Relevance: CaMKIIα mediates IL-17-driven pain in MS/EAE.[6] Curcumin directly inhibits CaMKIIα activity, preventing and reversing opioid tolerance.[Document] In EAE, curcumin improved clinical course and reduced Th17 cells.[7]

Omega-3 Evidence: A prospective study (468 participants, 11-year follow-up) found higher serum alpha-linolenic acid (ALA) levels were associated with lower risk of clinically definite MS (HR 0.60) and relapses (RR 0.65).[42] A meta-analysis showed omega-3 significantly reduced TNF-α in MS patients.[46]

—

Tier 3: Supporting Agents

Agent	Dosing Protocol	Mechanism/Rationale	References
Magnesium	400–500 mg daily (glycinate)	NMDA receptor antagonism; Enhances opioid analgesia; Neuroprotective	56
N-Acetyl Cysteine	600 mg BID	Enhances glutathione (reduced in MS); Reduces oxidative stress; Synergistic with ALA	[56 ][1]
Probiotics	Multi-strain formulation	MS clinical evidence: 12-week RCT showed favorable effects on disability, mood, inflammatory markers	[2]
Acetyl L Carnitine (ALC)	500–1000 mg BID	Trend toward benefit for MS fatigue; Neuroprotective; synergistic with PEA	[3]

[7][51]

—

PAIN TYPE-SPECIFIC PROTOCOLS

MS pain is heterogeneous; nutraceutical selection should be tailored to the predominant pain type:

1. Central Neuropathic Pain (Burning Dysesthesias, Ongoing Extremity Pain)

Priority	Agent	Dosing	Rationale	References
1st	PEA	600 mg BID	Effective for neuropathic pain (SMD -0.97); reduces glial activation	[1]
2nd	ALA	1200 mg daily	Neuroprotective; reduces neuroinflammation	[2], [3]
3rd	Melatonin	5–10 mg QHS	MT2 receptor-mediated descending modulation; sleep optimization	[4]
4th	Magnesium	400 mg daily	NMDA receptor antagonism	[56]
5th	Curcumin	500 mg TID	CaMKIIα inhibition; anti-inflammatory	[5]

[16][6][41][8]

2. Trigeminal Neuralgia

Priority	Agent	Dosing	Rationale	References
1st	Magnesium	400–500 mg daily	NMDA receptor antagonism; may enhance carbamazepine/oxcarbazepine	56
2nd	PEA	600 mg 2x/day	Neuroprotective; reduces neuroinflammation	[1]
3rd	Curcumin	500 mg 3x/day	Anti-inflammatory; May reduce nerve inflammation	[2]
4th	B-vitamins	B-complex daily	Neural support; synergistic with anticonvulsants	[3]

[52][16][3]

Note: Trigeminal neuralgia in MS requires pharmacological treatment (carbamazepine/oxcarbazepine first-line).[53][54] Nutraceuticals are adjunctive.

3. Spasticity-Related Pain

Priority	Agent	Dosing	Rationale	References
1st	Magnesium	400–500 mg daily	Muscle relaxation; NMDA antagonism	56
2nd	PEA	600 mg 2x/day	Effective for nociceptive pain	[1]
3rd	Omega-3	2 gm daily	Anti-inflammatory; may reduce muscle inflammation	[2]
4th	Vitamin D3	Optimize to 40–60 ng/mL	Muscle function; deficiency common in MS	[3]

[16][43][32]

4. Painful Tonic Spasms / Lhermitte’s Phenomenon

Priority	Agent	Dosing	Rationale	References
1st	Magnesium	400–500 mg daily	Reduces neuronal hyperexcitability	[56]
2nd	Melatonin	5–10 mg at night	Reduces oxidative stress; Neuroprotective	[1]
3rd	ALA	600–1200 mg daily	Antioxidant; neuroprotective	[2]

[40][8]

5. Treatment-Related Pain (IFN-β Injection Site Pain)

Priority

Agent

Dosing

Rationale

References

1st

PEA

600 mg 2x/day

Direct clinical evidence:

Reduced IFN-β1a injection site pain in RCT

[1]

2nd

Omega-3

2 g daily

Anti-inflammatory

[2]

[28][43]

—

COMPREHENSIVE MS PAIN PROTOCOL

Phase 1: Foundation (Weeks 1–4)

Vitamin D3: target ≥40 ng/mL
PEA (ultramicronized): 600 mg BID
Melatonin: 3–5 mg QHS (titrate to 10 mg if needed)
Magnesium glycinate: 400 mg daily

Phase 2: Intensification (Weeks 4–12)

Continue Phase 1 agents
Add ALA: 1200 mg daily
Add Omega-3: 2 g daily
Add Curcumin: 500 mg TID (high-bioavailability formulation)

Phase 3: Optimization (Weeks 12+)

Continue effective agents
Consider adding CoQ10 300 mg daily for fatigue
Consider adding Resveratrol 250–500 mg daily for additional neuroprotection
Consider NAC 600 mg BID for oxidative stress
Transition PEA to 600 mg QD if pain well-controlled

—

INTEGRATION WITH MS DISEASE-MODIFYING THERAPY

Nutraceuticals should complement, not replace, disease-modifying therapy (DMT). Several nutraceuticals may enhance DMT efficacy:

DMT	Nutraceutical Considerations	Rationale	References
Interferon-β	PEA, Vitamin D	PEA reduces injection site pain; Vitamin D may enhance efficacy (SOLAR, CHOLINE trials)	[1], [2], [3]
Glatiramer acetate	PEA, Omega-3	May reduce injection site reactions	[4]
Natalizumab	Standard protocol	No specific interactions	–
Fingolimod	Omega-3, Vitamin D	Cardiovascular support; immune modulation	[5]
Ocrelizumab	Standard protocol	No specific interactions	–

[28][33][34][55]

—

SPECIAL CONSIDERATIONS FOR MS

Fatigue: Fatigue is the most common MS symptom and exacerbates pain perception. CoQ10 (500 mg/day) reduced fatigue in an RCT.[7] L-carnitine showed a trend toward benefit.[7] Melatonin improves sleep quality, which may indirectly improve fatigue.[40]
Depression: Depression is common in MS and amplifies pain. PEA has demonstrated effects on mood in neurodegenerative conditions.[29] Melatonin reduces inflammatory markers associated with depression.[40] Omega-3 has antidepressant properties.
Cognitive Impairment: ALA showed neuroprotective effects with reduced brain atrophy.[7] Vitamin D optimization may support cognitive function.
Reduced Opioid Efficacy: Central amygdala microglial activation in MS attenuates morphine analgesia, particularly in females.[4] Nutraceuticals targeting microglial activation (PEA, melatonin, resveratrol) may help restore opioid responsiveness.

Drug Interactions:

ALA: May cause hypoglycemia; monitor in diabetic patients; potential renal effects at high doses[7]
Omega-3: May increase bleeding risk with anticoagulants; monitor INR with warfarin[7]
Resveratrol: May interact with medications metabolized by CYP enzymes; may increase bleeding[7]
Vitamin D: Monitor calcium levels; avoid in sarcoidosis & tuberculosis)[33]

—

PATIENT EDUCATION SUMMARY

Understanding Pain in Multiple Sclerosis

Pain is very common in multiple sclerosis (MS), affecting more than half of all patients. MS can cause several types of pain:

– Burning or tingling sensations in your arms or legs (central neuropathic pain)

– Sharp, electric shock-like pain in your face (trigeminal neuralgia)

– Muscle tightness and spasms (spasticity-related pain)

– Brief electric sensations down your spine when you bend your neck (Lhermitte’s sign)

– Pain at injection sites from MS medications

Your healthcare provider has recommended a supplement program designed to work alongside your MS medications to help manage pain and support your nervous system.

—

Your Core Supplements

Vitamin D3

– Your provider will check your vitamin D level with a blood test

– Many people with MS have low vitamin D, which may worsen symptoms

– Higher vitamin D levels are associated with fewer relapses and less disease activity

– Take as directed to reach your target level (usually 40–60 ng/mL or higher)

PEA (Palmitoylethanolamide) – 600 mg twice daily

– A natural substance that helps calm inflammation in your nervous system

– Has been studied specifically in MS patients

– May help reduce pain from your MS medications’ injection sites

– Generally very well tolerated

Melatonin – 3–10 mg at bedtime

– Helps improve sleep, which is often disrupted in MS

– Has natural anti-inflammatory properties

– Research shows melatonin levels are linked to MS disease activity

– May help reduce oxidative stress that damages nerves

Alpha-Lipoic Acid – 1200 mg daily

– A powerful antioxidant that protects nerve cells

– Has been studied in MS patients and may help slow brain changes

– Reduces inflammation in the nervous system

Magnesium – 400 mg daily

– Helps calm overactive nerve signals

– May help with muscle spasms and tightness

– Supports overall nerve function

—

Additional Helpful Supplements

Omega-3 Fish Oil – 2 grams daily

– Reduces inflammation throughout your body

– Higher levels are associated with fewer MS relapses

– Supports brain health

– If you take blood thinners, discuss with your doctor first

Curcumin – 500 mg three times daily

– A powerful anti-inflammatory from turmeric

– May help reduce nerve inflammation

– Use a high-absorption form as recommended

CoQ10 – 300 mg daily

– May help with MS-related fatigue

– Supports energy production in your cells

– Has anti-inflammatory effects

—

What to Expect

– Weeks 1–2: You may notice improved sleep with melatonin

– Weeks 2–4: Some people begin to notice reduced pain or improved energy

– Weeks 4–8: More noticeable improvements if supplements are helping

– Weeks 8–12: Full assessment of how well the program is working

Be patient – these supplements work gradually by addressing the underlying causes of your pain and supporting your nervous system.

—

Important Safety Information

Continue all your MS medications as prescribed

– Tell your healthcare provider about all supplements you take

– If you take blood thinners, discuss omega-3 fish oil with your doctor

– If you have diabetes, alpha-lipoic acid may affect blood sugar – monitor closely

– Most side effects are mild (stomach upset, drowsiness with melatonin)

When to Contact Your Healthcare Provider

– If your pain significantly worsens

– If you experience new neurological symptoms

– If you have unusual bleeding or bruising

– If you experience severe side effects

—

Tips for Success

1. Be consistent: Take supplements at the same time each day

2. Use a pill organizer: This helps track multiple supplements

3. Keep a symptom diary: Note your pain levels, fatigue, and sleep quality

4. Stay active: Gentle exercise as tolerated helps manage MS symptoms

5. Manage stress: Stress can worsen MS symptoms and pain

6. Prioritize sleep: Good sleep is essential for managing MS

—

Working With Your Healthcare Team

These supplements are meant to work alongside your MS medications, not replace them. Your neurologist and other healthcare providers should know about all supplements you take. Together, you can find the best combination of treatments to manage your MS symptoms and improve your quality of life.

—

Clinical Implementation Notes

The evidence for nutraceuticals in MS pain is a combination of MS-specific clinical trials, EAE (animal model) studies, and extrapolation from general neuropathic pain literature.

PEA has the most direct clinical evidence in MS, with an RCT demonstrating reduced injection site pain and decreased proinflammatory cytokines when added to IFN-β1a.[28] Meta-analyses confirm PEA’s efficacy across nociceptive, neuropathic, and nociplastic pain types.[16]

Vitamin D has emerging evidence for disease modification. The D-Lay MS trial (2025) showed high-dose vitamin D reduced disease activity with efficacy comparable to teriflunomide.[33] An updated meta-analysis (2025) found vitamin D supplementation significantly reduced EDSS scores, relapse rates, and new T2 lesions.[35]

Alpha-lipoic acid showed a 68% reduction in brain atrophy in a 2-year RCT in secondary progressive MS.[7] However, a larger phase 2 trial (2026) did not show clinical benefits on walking speed, though volumetric imaging suggested possible neuroprotection.[41]

Melatonin has strong mechanistic rationale, with evidence that melatonin levels negatively correlate with MS relapses and that melatonin blocks pathogenic Th17 differentiation.[39] A 12-week RCT demonstrated reduced oxidative stress and improved sleep in MS patients.[40]

Curcumin has robust EAE evidence but limited clinical MS data. Its direct inhibition of CaMKIIα[Document] is particularly relevant given CaMKIIα’s role in MS pain.[6]

Important caveats: MS pain is heterogeneous and often requires multimodal pharmacological treatment. Nutraceuticals should be viewed as adjunctive therapy. The Cochrane review of dietary interventions in MS found insufficient evidence for most supplements on MS-related outcomes, though the review focused on disease modification rather than pain specifically.[51]

References

Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes. Racke MK, Frohman EM, Frohman T. Frontiers in Neurology. 2021;12:799698. doi:10.3389/fneur.2021.799698.
Identifying and Treating Pain Caused by MS. Wright LJ. The Journal of Clinical Psychiatry. 2012;73(7):e23. doi:10.4088/JCP.11093nr1c.
Pharmacological and Non-Pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis. Shkodina AD, Bardhan M, Chopra H, et al. CNS Drugs. 2024;38(3):205-224. doi:10.1007/s40263-024-01072-5.
Central Amygdala Inflammation Drives Pain Hypersensitivity and Attenuates Morphine Analgesia in Experimental Autoimmune Encephalomyelitis. Dworsky-Fried Z, Faig CA, Vogel HA, Kerr BJ, Taylor AMW. Pain. 2022;163(1):e49-e61. doi:10.1097/j.pain.0000000000002307.
Multiple Sclerosis. Reich DS, Lucchinetti CF, Calabresi PA. The New England Journal of Medicine. 2018;378(2):169-180. doi:10.1056/NEJMra1401483.
CaMKIIα Mediates the Effect of IL-17 to Promote Ongoing Spontaneous and Evoked Pain in Multiple Sclerosis. Hu X, Huang F, Wang ZJ. The Journal of Neuroscience : The Official Journal of the Society for Neuroscience. 2018;38(1):232-244. doi:10.1523/JNEUROSCI.2666-17.2017.
Use of Vitamins and Dietary Supplements by Patients With Multiple Sclerosis: A Review. Evans E, Piccio L, Cross AH. JAMA Neurology. 2018;75(8):1013-1021. doi:10.1001/jamaneurol.2018.0611.
Role of Lipoic Acid in Multiple Sclerosis. Xie H, Yang X, Cao Y, et al. CNS Neuroscience & Therapeutics. 2022;28(3):319-331. doi:10.1111/cns.13793.
Resveratrol Defends Blood-Brain Barrier Integrity in Experimental Autoimmune Encephalomyelitis Mice. Wang D, Li SP, Fu JS, et al. Journal of Neurophysiology. 2016;116(5):2173-2179. doi:10.1152/jn.00510.2016.
Endoplasmic Reticulum Stress in the Dorsal Root Ganglia Regulates Large-Conductance Potassium Channels and Contributes to Pain in a Model of Multiple Sclerosis. Yousuf MS, Samtleben S, Lamothe SM, et al. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2020;34(9):12577-12598. doi:10.1096/fj.202001163R.
A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET. Sayed D, Deer TR, Hagedorn JM, et al. Journal of Pain Research. 2024;17:1461-1501. doi:10.2147/JPR.S451006.
The Role of Diet and Non-Pharmacologic Supplements in the Treatment of Chronic Neuropathic Pain: A Systematic Review. Frediani JK, Lal AA, Kim E, et al. Pain Practice : The Official Journal of World Institute of Pain. 2024;24(1):186-210. doi:10.1111/papr.13291.
The Neuroprotective Effects of Micronized PEA (PEA-m) Formulation on Diabetic Peripheral Neuropathy in Mice. Impellizzeri D, Peritore AF, Cordaro M, et al. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2019;33(10):11364-11380. doi:10.1096/fj.201900538R.
Pathogenetic Treatments for Diabetic Peripheral Neuropathy. Ziegler D. Diabetes Research and Clinical Practice. 2023;206 Suppl 1:110764. doi:10.1016/j.diabres.2023.110764.
Biomarkers of Response to Alpha-Lipoic Acid ± palmitoiletanolamide Treatment in Patients With Diabetes and Symptoms of Peripheral Neuropathy. Pieralice S, Vari R, Minutolo A, et al. Endocrine. 2019;66(2):178-184. doi:10.1007/s12020-019-01917-w.
Meta-Analysis of Palmitoylethanolamide in Pain Management: Addressing Literature Gaps and Enhancing Understanding. Viña I, López-Moreno M. Nutrition Reviews. 2025;83(7):e1604-e1618. doi:10.1093/nutrit/nuae203.
Nutraceutical Approach to Peripheral Neuropathies: Evidence From Clinical Trials. Mostacci B, Liguori R, Cicero AF. Current Drug Metabolism. 2018;19(5):460-468. doi:10.2174/1389200218666171031145419.
Dietary and Nutritional Supplementation for Painful Diabetic Neuropathy: A Narrative Review. Apergi K, Papanas N. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association. 2023;131(12):646-655. doi:10.1055/a-2188-1745.
Diabetic Peripheral Neuropathy: Prevention and Treatment. Bragg S, Marrison ST, Haley S. American Family Physician. 2024;109(3):226-232.
Nociplastic Pain: Towards an Understanding of Prevalent Pain Conditions. Fitzcharles MA, Cohen SP, Clauw DJ, et al. Lancet (London, England). 2021;397(10289):2098-2110. doi:10.1016/S0140-6736(21)00392-5.
Review of Nutritional Approaches to Fibromyalgia. Kadayifci FZ, Bradley MJ, Onat AM, Shi HN, Zheng S. Nutrition Reviews. 2022;80(12):2260-2274. doi:10.1093/nutrit/nuac036.
Fibromyalgia and Nutrition: Therapeutic Possibilities?. Bjørklund G, Dadar M, Chirumbolo S, Aaseth J. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2018;103:531-538. doi:10.1016/j.biopha.2018.04.056.
Serum Magnesium Levels and Their Association With Sleep Quality and Disease Severity in Fibromyalgia Syndrome: An Observational Cross-Sectional Study. Alisik T, Reis Altan YC, Olkay SG, Sahingoz Bakirci E. Medicine. 2025;104(29):e43446. doi:10.1097/MD.0000000000043446.
Is Magnesium Citrate Treatment Effective on Pain, Clinical Parameters and Functional Status in Patients With Fibromyalgia?. Bagis S, Karabiber M, As I, et al. Rheumatology International. 2013;33(1):167-72. doi:10.1007/s00296-011-2334-8.
Psychological and Sleep Effects of Tryptophan and Magnesium-Enriched Mediterranean Diet in Women With Fibromyalgia. Martínez-Rodríguez A, Rubio-Arias JÁ, Ramos-Campo DJ, et al. International Journal of Environmental Research and Public Health. 2020;17(7):E2227. doi:10.3390/ijerph17072227.
Targeted Treatment of Age-Related Fibromyalgia With Supplemental Coenzyme Q10. Hargreaves IP, Mantle D. Advances in Experimental Medicine and Biology. 2021;1286:77-85. doi:10.1007/978-3-030-55035-6_5.
Bioactive Compounds for Fibromyalgia-Like Symptoms: A Narrative Review and Future Perspectives. Shen CL, Schuck A, Tompkins C, Dunn DM, Neugebauer V. International Journal of Environmental Research and Public Health. 2022;19(7):4148. doi:10.3390/ijerph19074148.
Oral Palmitoylethanolamide Treatment Is Associated With Reduced Cutaneous Adverse Effects of Interferon-Β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis. Orefice NS, Alhouayek M, Carotenuto A, et al. Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics. 2016;13(2):428-38. doi:10.1007/s13311-016-0420-z.
Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review From Rodents to Humans. Landolfo E, Cutuli D, Petrosini L, Caltagirone C. Biomolecules. 2022;12(5):667. doi:10.3390/biom12050667.
Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-Analysis. Paladini A, Fusco M, Cenacchi T, et al. Pain Physician. 2016;19(2):11-24.
Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Scuteri D, Guida F, Boccella S, et al. Pharmaceutics. 2022;14(8):1672. doi:10.3390/pharmaceutics14081672.
Vitamin D for the Management of Multiple Sclerosis. Jagannath VA, Filippini G, Di Pietrantonj C, et al. The Cochrane Database of Systematic Reviews. 2018;9:CD008422. doi:10.1002/14651858.CD008422.pub3.
High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. Thouvenot E, Laplaud D, Lebrun-Frenay C, et al. JAMA. 2025;333(16):1413-1422. doi:10.1001/jama.2025.1604.
An Update on Vitamin D and Disease Activity in Multiple Sclerosis. Smolders J, Torkildsen Ø, Camu W, Holmøy T. CNS Drugs. 2019;33(12):1187-1199. doi:10.1007/s40263-019-00674-8.
Role of Vitamin D as Adjuvant Therapy on Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Serag I, Abouzid M, Alsaadany KR, et al. European Journal of Medical Research. 2025;30(1):736. doi:10.1186/s40001-025-02981-x.
Melatonin Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis by Modulating the Kynurenine Pathway. Jand Y, Ghahremani MH, Ghanbari A, et al. Scientific Reports. 2022;12(1):15963. doi:10.1038/s41598-022-20164-0.
Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence. Yeganeh Salehpour M, Mollica A, Momtaz S, Sanadgol N, Farzaei MH. Clinical Drug Investigation. 2019;39(7):607-624. doi:10.1007/s40261-019-00793-6.
Melatonin Reduces Inflammatory Response in Peripheral T Helper Lymphocytes From Relapsing-Remitting Multiple Sclerosis Patients. Álvarez-Sánchez N, Cruz-Chamorro I, Díaz-Sánchez M, et al. Journal of Pineal Research. 2017;63(4). doi:10.1111/jpi.12442.
Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Farez MF, Mascanfroni ID, Méndez-Huergo SP, et al. Cell. 2015;162(6):1338-52. doi:10.1016/j.cell.2015.08.025.
12-Week Melatonin Intake Attenuates Cardiac Autonomic Dysfunction and Oxidative Stress in Multiple Sclerosis Patients: A Randomized Controlled Trial. Jallouli S, Jallouli D, Damak M, et al. Metabolic Brain Disease. 2024;40(1):52. doi:10.1007/s11011-024-01428-2.
Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial. Spain RI, Paz Soldán MM, Freedman MS, et al. Neurology. 2026;106(1):e214454. doi:10.1212/WNL.0000000000214454.
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression. Cortese M, Peng X, Edan G, et al. Neurology. 2025;105(3):e213905. doi:10.1212/WNL.0000000000213905.
Effect of Omega-3 Fatty Acids and Fish Oil Supplementation on Multiple Sclerosis: A Systematic Review. AlAmmar WA, Albeesh FH, Ibrahim LM, et al. Nutritional Neuroscience. 2021;24(7):569-579. doi:10.1080/1028415X.2019.1659560.
Role of Omega-3 Endocannabinoids in the Modulation of T-Cell Activity in a Multiple Sclerosis Experimental Autoimmune Encephalomyelitis (EAE) Model. Kim JS, Soto-Diaz K, Bingham TW, Steelman AJ, Das A. The Journal of Biological Chemistry. 2023;299(2):102886. doi:10.1016/j.jbc.2023.102886.
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Yadav V, Bever C, Bowen J, et al. Neurology. 2014;82(12):1083-92. doi:10.1212/WNL.0000000000000250.
The Effects of Omega-3 Supplementation on the Expanded Disability Status Scale and Inflammatory Cytokines in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. Sedighiyan M, Djafarian K, Dabiri S, Abdolahi M, Shab-Bidar S. CNS & Neurological Disorders Drug Targets. 2019;18(7):523-529. doi:10.2174/1871527318666190516083008.
Curcumin Regulates Anti-Inflammatory Responses by AXL/JAK2/STAT3 Signaling Pathway in Experimental Autoimmune Encephalomyelitis. Sun M, Liu N, Sun J, et al. Neuroscience Letters. 2022;787:136821. doi:10.1016/j.neulet.2022.136821.
Curcumin and Targeting of Molecular and Metabolic Pathways in Multiple Sclerosis. Yazdani Y, Zamani ARN, Majidi Z, et al. Cell Biochemistry and Function. 2023;41(7):779-787. doi:10.1002/cbf.3841.
Curcumin as a Therapeutic Candidate for Multiple Sclerosis: Molecular Mechanisms and Targets. Ghanaatian N, Lashgari NA, Abdolghaffari AH, et al. Journal of Cellular Physiology. 2019;234(8):12237-12248. doi:10.1002/jcp.27965.
Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis. Gachpazan M, Habbibirad S, Kashani H, et al. Advances in Experimental Medicine and Biology. 2021;1291:41-53. doi:10.1007/978-3-030-56153-6_3.
Dietary Interventions for Multiple Sclerosis-Related Outcomes. Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC. The Cochrane Database of Systematic Reviews. 2020;5:CD004192. doi:10.1002/14651858.CD004192.pub4.
Non-Drug Pain Relievers Active on Non-Opioid Pain Mechanisms. Marchesi N, Govoni S, Allegri M. Pain Practice : The Official Journal of World Institute of Pain. 2022;22(2):255-275. doi:10.1111/papr.13073.
Pharmacological Management of Symptoms in Multiple Sclerosis: Current Approaches and Future Directions. Thompson AJ, Toosy AT, Ciccarelli O. The Lancet. Neurology. 2010;9(12):1182-1199. doi:10.1016/S1474-4422(10)70249-0.
Trigeminal Neuralgia. Cruccu G, Di Stefano G, Truini A. The New England Journal of Medicine. 2020;383(8):754-762. doi:10.1056/NEJMra1914484.
Current Management of Pain Associated With Multiple Sclerosis. Pöllmann W, Feneberg W. CNS Drugs. 2008;22(4):291-324. doi:10.2165/00023210-200822040-00003.
Nutraceutical Interactions with Opioid Pain Processing

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.